IP Library › Granted Patent US 12,473,373
Granted Patent B2
US 12,473,373 · App. 18/244,135 · Granted Nov 18, 2025

Bispecific antibody molecules binding to CD3 and EGFRvIII

Inventors: Anne Freimoser-Grundschober (Schlieren, CH); Thomas Hofer (Schlieren, CH); Ralf Hosse (Schlieren, CH); Ekkehard Moessner (Schlieren, CH); Valeria G. Nicolini (Schlieren, CH); Pablo Umaña (Schlieren, CH); Inja Waldhauer (Schlieren, CH); Wolfgang Richter (Basel, CH); Alexander Knaupp (Penzberg, DE); Halina Trochanowska (Schlieren, CH)
Assignee: Hoffmann-La Roche Inc.
C07K16/3053A61K39/39558A61P35/00C07K16/2809C07K16/2863A61K2039/505C07K2317/31C07K2317/55C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,473,373
App. No.
18/244,135
Granted
Nov 18, 2025
Kind
B2
Abstract

The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Claims (49)

1 . A bispecific antibody molecule that binds to EGFRvIII and CD3 comprising:

(a) a first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain comprises: a VH comprising a HCDR 1 comprising the amino acid sequence SYAMN (SEQ ID NO: 2), a HCDR 2 comprising the amino acid sequence RIRSKYNNYATYYADSVKG (SEQ ID NO: 3), and a HCDR 3 comprising the amino acid sequence HTTFPSSYVSYYGY (SEQ ID NO: 5), and a VL comprising a LCDR 1 comprising the amino acid sequence GSSTGAVTTSNYAN (SEQ ID NO: 8), a LCDR 2 comprising the amino acid sequence GTNKRAP (SEQ ID NO: 9), and a LCDR 3 comprising the amino acid sequence ALWYSNLWV (SEQ ID NO: 10);

(b) a second antigen-binding domain that binds to EGFRvIII, wherein the second antigen-binding domain comprises: a VH comprising a HCDR 1 comprising the amino acid sequence SYWIA (SEQ ID NO: 85, a HCDR 2 comprising the amino acid sequence VIHPYDSDTRYSPSFQG (SEQ ID NO: 86), and a HCDR 3 comprising the amino acid sequence VSRSSYAFDY (SEQ ID NO: 87), and a VL comprising a LCDR 1 comprising the amino acid sequence KSSQSVLYSSNNKNYLA (SEQ ID NO: 89), a LCDR 2 comprising the amino acid sequence WASTRES (SEQ ID NO: 90), and a LCDR 3 comprising the amino acid sequence QQQRDGPPVT (SEQ ID NO: 91);

(c) a third antigen-binding domain that binds to EGFRvIII, wherein the third antigen-binding domain comprises: a VH comprising a HCDR 1 comprising the amino acid sequence SYWIA (SEQ ID NO: 85), a HCDR 2 comprising the amino acid sequence VIHPYDSDTRYSPSFQG (SEQ ID NO: 86), and a HCDR 3 comprising the amino acid sequence VSRSSYAFDY (SEQ ID NO: 87), and a VL comprising a LCDR 1 comprising the amino acid sequence KSSQSVLYSSNNKNYLA (SEQ ID NO: 89), a LCDR 2 comprising the amino acid sequence WASTRES (SEQ ID NO: 90), and a LCDR 3 comprising the amino acid sequence QQQRDGPPVT (SEQ ID NO: 91); and

(d) an Fc domain comprising a first subunit and a second subunit, wherein the Fc domain is a human IgG Fc domain.

2 . The bispecific antibody molecule of claim 1 , wherein the Fc domain is a human IgG 1 Fc domain.

3 . The bispecific antibody molecule of claim 2 , wherein each of the first antigen-binding domain, the second antigen-binding domain, and the third antigen-binding domain is a Fab molecule, wherein: (a) the first antigen-binding domain is a crossover Fab molecule, wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other; and (b) each of the second antigen-binding domain and the third antigen-binding domain is a conventional Fab molecule,

wherein the third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain, the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain.

4 . The bispecific antibody molecule of claim 3 , wherein in the constant domain CL of each of the second antigen-binding domain and the third antigen-binding domain, the amino acid at position 124 is substituted for lysine (K), wherein the amino acid position is numbered according to Kabat, and the amino acid at position 123 is substituted for arginine (R), wherein the amino acid position is numbered according to Kabat, and in the constant domain CH1 of each the second antigen-binding domain and the third antigen-binding domain, the amino acid at position 147 is substituted for glutamic acid (E), wherein the amino acid position is numbered according to the Kabat EU index, and the amino acid at position 213 is substituted for glutamic acid (E), wherein the amino acid position is numbered according to the Kabat EU index.

5 . The bispecific antibody molecule of claim 4 , wherein the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W, and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V, wherein each of the amino acid positions is numbered according to the Kabat EU index.

6 . The bispecific antibody molecule of claim 5 , wherein each subunit of the Fc domain comprises the amino acid substitutions L234A, L235A, and P329G, wherein each of the amino acid positions is numbered according to the Kabat EU index.

7 . The bispecific antibody molecule of claim 1 , wherein:

(a) the first antigen-binding domain comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 7 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11;

(b) the second antigen-binding domain comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 88 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 92; and

(c) the third antigen-binding domain comprises a VH that is at least 95% identical to the amino acid sequence of SEQ ID NO: 88 and a VL that is at least 95% identical to the amino acid sequence of SEQ ID NO: 92.

8 . The bispecific antibody molecule of claim 7 , wherein each of the first antigen-binding domain, the second antigen-binding domain, and the third antigen-binding domain is a Fab molecule, wherein: (a) the first antigen-binding domain is a crossover Fab molecule, wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other; and (b) each of the second antigen-binding domain and the third antigen-binding domain is a conventional Fab molecule,

wherein the third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain, the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain.

9 . The bispecific antibody molecule of claim 8 , wherein the bispecific antibody comprises one or more of the following modifications:

(a) in the constant domain CL of each of the second antigen-binding domain and the third antigen-binding domain, the amino acid at position 124 is substituted for lysine (K), wherein the amino acid position is numbered according to Kabat, and the amino acid at position 123 is substituted for arginine (R), wherein the amino acid position is numbered according to Kabat, and in the constant domain CH1 of each the second antigen-binding domain and the third antigen-binding domain, the amino acid at position 147 is substituted for glutamic acid (E), wherein the amino acid position is numbered according to the Kabat EU index, and the amino acid at position 213 is substituted for glutamic acid (E), wherein the amino acid position is numbered according to the Kabat EU index;

(b) the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W, and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V, wherein each of the amino acid positions is numbered according to the Kabat EU index; and

(c) each subunit of the Fc domain comprises the amino acid substitutions L234A, L235A, and P329G, wherein each of the amino acid positions is numbered according to the Kabat EU index.

10 . The bispecific antibody molecule of claim 9 , wherein in the constant domain CL of each of the second antigen-binding domain and the third antigen-binding domain, the amino acid at position 124 is substituted for lysine (K), wherein the amino acid position is numbered according to Kabat, and the amino acid at position 123 is substituted for arginine (R), wherein the amino acid position is numbered according to Kabat, and in the constant domain CH1 of each the second antigen-binding domain and the third antigen-binding domain, the amino acid at position 147 is substituted for glutamic acid (E), wherein the amino acid position is numbered according to the Kabat EU index, and the amino acid at position 213 is substituted for glutamic acid (E), wherein the amino acid position is numbered according to the Kabat EU index.

11 . The bispecific antibody molecule of claim 10 , wherein the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W, and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V, wherein each of the amino acid positions is numbered according to the Kabat EU index.

12 . The bispecific antibody molecule of claim 11 , wherein each subunit of the Fc domain comprises the amino acid substitutions L234A, L235A, and P329G, wherein each of the amino acid positions is numbered according to the Kabat EU index.

13 . The bispecific antibody molecule of claim 1 , wherein the bispecific antibody molecule comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 109, a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 110, two polypeptides comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 111, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 27.

14 . The bispecific antibody molecule of claim 6 , wherein the bispecific antibody molecule comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 109, a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 110, two polypeptides comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 111, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 27.

15 . A pharmaceutical composition comprising the bispecific antibody molecule of claim 1 and a pharmaceutically acceptable carrier.

16 . A pharmaceutical composition comprising the bispecific antibody molecule of claim 13 and a pharmaceutically acceptable carrier.

17 . A pharmaceutical composition comprising the bispecific antibody molecule of claim 14 and a pharmaceutically acceptable carrier.

18 . A bispecific antibody molecule that binds to EGFRvIII and CD3 comprising:

(a) a first antigen-binding domain that binds to CD3, wherein the first antigen-binding domain comprises: a VH comprising the amino acid sequence of SEQ ID NO: 7 and a VL comprising the amino acid sequence of SEQ ID NO: 11;

(b) a second antigen-binding domain that binds to EGFRvIII, wherein the second antigen-binding domain comprises: a VH comprising the amino acid sequence of SEQ ID NO: 88 and a VL comprising the amino acid sequence of SEQ ID NO: 92;

(c) a third antigen-binding domain that binds to EGFRvIII, wherein the third antigen-binding domain comprises: a VH comprising the amino acid sequence of SEQ ID NO: 88 and a VL comprising the amino acid sequence of SEQ ID NO: 92; and

(d) a human IgG Fc domain comprising a first subunit and a second subunit.

19 . The bispecific antibody molecule of claim 18 , wherein the Fc domain is a human IgG 1 Fc domain.

20 . The bispecific antibody molecule of claim 19 , wherein each of the first antigen-binding domain, the second antigen-binding domain, and the third antigen-binding domain is a Fab molecule, wherein: (a) the first antigen-binding domain is a crossover Fab molecule, wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other; and (b) each of the second antigen-binding domain and the third antigen-binding domain is a conventional Fab molecule, wherein the third antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain, the second antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen-binding domain, and the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain.

21 . The bispecific antibody molecule of claim 20 , wherein the bispecific antibody comprises one or more of the following modifications:

(a) in the constant domain CL of each of the second antigen-binding domain and the third antigen-binding domain, the amino acid at position 124 is substituted for lysine (K), wherein the amino acid position is numbered according to Kabat, and the amino acid at position 123 is substituted for arginine (R), wherein the amino acid position is numbered according to Kabat, and in the constant domain CH1 of each the second antigen-binding domain and the third antigen-binding domain, the amino acid at position 147 is substituted for glutamic acid (E), wherein the amino acid position is numbered according to the Kabat EU index, and the amino acid at position 213 is substituted for glutamic acid (E), wherein the amino acid position is numbered according to the Kabat EU index;

(b) the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W, and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V, wherein each of the amino acid positions is numbered according to the Kabat EU index; and

(c) each subunit of the Fc domain comprises the amino acid substitutions L234A, L235A, and P329G, wherein each of the amino acid positions is numbered according to the Kabat EU index.

22 . The bispecific antibody molecule of claim 21 , wherein in the constant domain CL of each of the second antigen-binding domain and the third antigen-binding domain, the amino acid at position 124 is substituted for lysine (K), wherein the amino acid position is numbered according to Kabat, and the amino acid at position 123 is substituted for arginine (R), wherein the amino acid position is numbered according to Kabat, and in the constant domain CH1 of each the second antigen-binding domain and the third antigen-binding domain, the amino acid at position 147 is substituted for glutamic acid (E), wherein the amino acid position is numbered according to the Kabat EU index, and the amino acid at position 213 is substituted for glutamic acid (E), wherein the amino acid position is numbered according to the Kabat EU index.

23 . The bispecific antibody molecule of claim 22 , wherein the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W, and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V, wherein each of the amino acid positions is numbered according to the Kabat EU index.

24 . The bispecific antibody molecule of claim 23 , wherein each subunit of the Fc domain comprises the amino acid substitutions L234A, L235A, and P329G, wherein each of the amino acid positions is numbered according to the Kabat EU index.

25 . The bispecific antibody molecule of claim 18 , wherein the bispecific antibody molecule comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 109, a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 110, two polypeptides comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 111, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 27.

26 . The bispecific antibody molecule of claim 24 , wherein the bispecific antibody molecule comprises a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 109, a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 110, two polypeptides comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 111, and a polypeptide comprising an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 27.

27 . A pharmaceutical composition comprising the bispecific antibody molecule of claim 18 and a pharmaceutically acceptable carrier.

28 . A pharmaceutical composition comprising the bispecific antibody molecule of claim 24 and a pharmaceutically acceptable carrier.

29 . A bispecific antibody molecule that binds to EGFRvIII and CD3 comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 109, a polypeptide comprising the amino acid sequence of SEQ ID NO: 110, two polypeptides comprising the amino acid sequence of SEQ ID NO: 111, and a polypeptide comprising the amino acid sequence of SEQ ID NO: 27.

30 . A pharmaceutical composition comprising the bispecific antibody molecule of claim 29 and a pharmaceutically acceptable carrier.

Priority Claims (1)
EP 18214994 · Dec 21, 2018 · regional
Continuity (3)
Division 18307400 · Apr 26, 2023
Division 16721254 · Dec 19, 2019
Related Publication 20240042022A1 · Feb 8, 2024
References Cited (65)
US 11591397B2 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 11608376B2 · Georges et al. · 2023 [cited by applicant]
US 11672858B2 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 11780920B2 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 12215155B2 · Freimoser-Grundschober et al. · 2025 [cited by applicant]
US 20070071675A1 · Wu et al. · 2007 [cited by applicant]
US 20130078249A1 · Ast et al. · 2013 [cited by applicant]
US 20160075785A1 · Ast et al. · 2016 [cited by applicant]
US 20160145354A1 · Bacac et al. · 2016 [cited by applicant]
US 20200199234A1 · Georges et al. · 2020 [cited by applicant]
US 20200270347A1 · Freimoser-Grundschober et al. · 2020 [cited by applicant]
US 20210403562A1 · Freimoser-Grundschober et al. · 2021 [cited by applicant]
US 20220010014A1 · Freimoser-Grundschober et al. · 2022 [cited by applicant]
US 20220213199A1 · Bujotzek et al. · 2022 [cited by applicant]
US 20220259318A1 · Bujotzek et al. · 2022 [cited by applicant]
US 20230159642A1 · Bujotzek et al. · 2023 [cited by applicant]
US 20230416365A1 · Georges et al. · 2023 [cited by applicant]
US 20230416411A1 · Bruenker et al. · 2023 [cited by applicant]
US 20240043535A1 · Amann et al. · 2024 [cited by applicant]
US 20240132590A1 · Freimoser-Grundschober et al. · 2024 [cited by applicant]
CL 2015001988A1 · 2015 [cited by applicant]
CL 2017000954A1 · 2017 [cited by applicant]
CL 2018000263A1 · 2018 [cited by applicant]
CN 104936986A · 2015 [cited by applicant]
CN 107074955A · 2017 [cited by applicant]
CN 107922495A · 2018 [cited by applicant]
WO WO0177342A1 · 2001 [cited by applicant]
WO WO2009114585A1 · 2009 [cited by applicant]
WO WO2010095031A2 · 2010 [cited by applicant]
WO WO2013078249A1 · 2013 [cited by applicant]
WO WO2014028748A1 · 2014 [cited by applicant]
WO WO2014131712A1 · 2014 [cited by applicant]
WO WO2016079076A1 · 2016 [cited by applicant]
WO WO2017021370A1 · 2017 [cited by applicant]
WO WO2017055393A1 · 2017 [cited by applicant]
WO WO2020127618A1 · 2020 [cited by applicant]
WO WO2021018859A2 · 2021 [cited by applicant]
WO WO2021255138A1 · 2021 [cited by applicant]
WO WO2021255143A1 · 2021 [cited by applicant]
WO WO2021255146A1 · 2021 [cited by applicant]
WO WO2021255155A1 · 2021 [cited by applicant]
WO WO2022129120A1 · 2022 [cited by applicant]
Baeuerle et al., “Bispecific T-cell engaging antibodies for cancer therapy,” Cancer Res. 69(12):4941-4 (Jun. 2009) (5 pages). [cited by applicant]
Chapter 9: Structure and Function of Immunoglobulins, [cited by applicant]
Choi et al., “Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma,” Proc Natl Acad Sci U S A. 110(1):270-5 (Jan. 2013). [cited by applicant]
Cuzick et al., “Overview of the main outcomes in breast-cancer prevention trials,” Lancet. 361(9354):296-300 (2003). [cited by applicant]
Evans et al., “Vaccine therapy for cancer—fact or fiction?,” QJM. 92(6):299-307 (1999). [cited by applicant]
Frankel et al., “Targeting T cells to tumor cells using bispecific antibodies,” Curr Opin Chem Biol. 17(3):385-92 (Jun. 2013). [cited by applicant]
Gedeon et al., “A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma,” Clin Cancer Res. 24(15):3611-3631 (Aug. 2018). [cited by applicant]
Haberger et al. “Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes,” MAbs. 6(2):327-39 (2014). [cited by applicant]
Haberger et al., “Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptability vs. functionality of critical quality attributes,” MAbs. 6(2):327-39 (2014) (24 pages). [cited by applicant]
Hernández-Ledesma et al., “Lunasin, a novel seed peptide for cancer prevention,” Peptides. 30(2):426-430 (2009). [cited by applicant]
Lurlaro et al., “A novel EGFRvIII-T cell bispecific antibody for the treatment of glioblastoma,” Mol Cancer Ther. 21(10):1499-1509. <https://pubmed.ncbi.nlm.nih.gov/35915983/>, retrieved on Aug. 4, 2022 (2022) (25 pages… [cited by applicant]
Kearns et al., “Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic,” Mol Cancer Ther. 14(7):1625-36 (2015). [cited by applicant]
Komenaka et al., “Immunotherapy for melanoma,” Clin Dermatol. 22(3):251-265 (2004). [cited by applicant]
Lu et al. “Deamidation and isomerization liability analysis of 131 clinical-stage antibodies,” MAbs. 11(1):45-57 (Jan. 2019). [cited by applicant]
Lu et al., “Deamidation and isomerization liability analysis of 131 clinical-stage antibodies,” MAbs. 11(1):45-57 (Dec. 10, 2018) (14 pages). [cited by applicant]
Munodzana et al., “Conformational dependence of anaplasma marginale major surface protein 5 surface-exposed B-cell epitopes,” Infection and Immunity. 66(6):2619-2624 (1998). [cited by applicant]
Polyak et al., “Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirement imposed by … [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci USA. 79(6):1979-1983 (1982). [cited by applicant]
Schiffman et al., “The promise of global cervical-cancer prevention,” N Engl J Med. 353(20):2101-2104 (2005). [cited by applicant]
Staerz et al., “Hybrid antibodies can target sites for attack by T cells,” Nature. 314(6012):628-31 (Apr. 1985). [cited by applicant]
Sydow et al. “Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions,” PLoS One. 9(6):e100736 (2014) (13 pages). [cited by applicant]
Sydow et al., “Structure-Based Prediction of Asparagine and Aspartate Degradation Sites in Antibody Variable Regions,” PLoS One. 9(6):e100736 (2014) (16 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2019/086144, mailed Apr. 9, 2020 (17 pages). [cited by applicant]
Cited By (1)
US 12,715,923